ArticleScientific reports2022
Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Diagnosis of heart failure with preserved ejection fraction: a systematic narrative review of the evidence.Heart failure reviews · 2024Pooled it
- Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction.Scientific reports · 2023Trial
- Plasma CA125 as a Prognostic Marker in Very Elderly Patients Hospitalized for Acute Heart Failure.Journal of clinical medicine · 2026Article
- From Tumor Marker to Congestion Indicator: The Expanding Role of CA-125 in Heart Failure and Beyond.Health science reports · 2026Article
- The Expanding Role of Carbohydrate Antigen 125 in Heart Failure: From Tumour Marker to a Cornerstone of Heart Failure Management. An Updated Narrative Review.Cardiac failure review · 2026Review
- Carbohydrate antigen 125 determined on arrival at the emergency department correlates with severity of decompensation and adverse outcomes in patients with acute heart failure.Internal and emergency medicine · 2026Article
- Carbohydrate antigen-125 (CA125): a marker of right ventricular dysfunction and poor prognosis in heart failure with preserved ejection fraction.International journal of cardiology. Heart & vasculature · 2025Article
- Article
- CA125 as a Potential Biomarker in Non-Malignant Serous Effusions: Diagnostic and Prognostic Considerations.Journal of clinical medicine · 2025Review
- Serum CA125: a prognostic biomarker for mortality in chronic heart failure.BMC cardiovascular disorders · 2025Article
- Biomarkers for Congestion in Heart Failure: State-of-the-art and Future Directions.Cardiac failure review · 2025Review
- Biomarkers in Heart Failure with Preserved Ejection Fraction: A Perpetually Evolving Frontier.Journal of clinical medicine · 2024Review
- CA125 outperforms NT-proBNP in the prediction of maximum aerobic capacity in heart failure with preserved ejection fraction and kidney dysfunction.Clinical kidney journal · 2024Article
- Carbohydrate antigen 125: a useful marker of congestion, fibrosis, and prognosis in heart failure with preserved ejection fraction.ESC heart failure · 2024Article
- Carbohydrate Antigen 125 (CA 125): A Novel Biomarker in Acute Heart Failure.Diagnostics (Basel, Switzerland) · 2024Review
- Prognostic significance of carbohydrate antigen 125 in stage D heart failure.BMC cardiovascular disorders · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
We aimed to assess the association between CA125 and the long-term risk of total acute heart failure (AHF) admissions in patients with an index hospitalization with AHF and preserved ejection fraction (HFpEF). We prospectively included 2369 patients between 2008 and 2019 in three centers. CA125 and NT-proBNP were measured during early hospitalization and evaluated as continuous and categorized in quartiles (Q). Negative binomial regressions were used to assess the association with the risk of recurrent AHF admission. The mean age of the sample patients was 76.7 ± 9.5 years and 1443 (60.9%) were women. Median values of CA125 and NT-proBNP were 38.3 (19.0-90.0) U/mL, and 2924 (1590-5447) pg/mL, respectively. During a median follow-up of 2.2 (0.8-4.6) years, 1200 (50.6%) patients died, and 2084 AHF admissions occurred in 1029 (43.4%) patients. After a multivariate adjustment, CA125, but not NT-proBNP, was positively and non-linearly associated with the risk of cumulative AHF-readmission (p < 0.001). Compared to Q1, patients belonging to Q2, Q3, and Q4 showed a stepwise risk increase (IRR = 1.29, 95% CI 1.08-1.55, p = 0.006; IRR = 1.35, 95% CI 1.12-1.63, p = 0.002; and IRR = 1.62, 95% CI 01.34-1.96, p < 0.001, respectively). In conclusion, CA125 predicted the risk of long-term AHF-readmission burden in patients with HFpEF and a recent admission for AHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.